Abstract
Adoptive transfer of antigen–specific cytotoxic T lymphocytes (CTLs) offers safe and effective therapy for certain viral infections and could prove useful in the eradication of tumor cells. Whether or not the infused T cells persist for extended periods, retaining their ability to expand in response to antigenic stimulation, is not known. We now report long–term detection of gene–marked Epstein–Barr virus (EBV)–specific CTLs in immunocompromised patients at risk for the development of EBV lymphoproliferative disease. Infusions of CTLs not only restored cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months. Our findings support wider use of antigen–specific CTLs in adoptive immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kolb, H.J. et al. Graft-versus-leukemia effect of donor leukocyte infusions in marrow grafted patients. Blood 86, 2041–2050 (1995).
Papadopoulos, E.B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994).
Heslop, H.E., Brenner, M.K. & Rooney, C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994).
Walter, E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038–1044 (1995).
Rooney, C.M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
Riddell, S.R. & Greenberg, P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545–586 (1995).
Smith, C.A. et al. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J. Hematother. 4, 73–79 (1995).
Reittie, J.E. et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73, 1351–1358 (1989).
Bourgault, I., Gomez, A., Gomard, E. & Levy, J.P. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin. Exp. Immunol. 84, 501–507 (1991).
Rooney, C.M. et al. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br. J. Haematol. 89, 98–103 (1995).
Matloubian, M., Concepcion, R.J. & Ahmed, R. CD4+ T cells are required to sustain CD8+ cytotoxic T cell responses during chronic viral infection. J. Virol. 68, 8056–8063 (1994).
Oehen, S., Waldner, H., Kundig, T.M., Hengartner, H. & Zinkernagel, R.M. Antivirally protected cytotoxic T cell memory to lymphocytic choriomeningitis is governed by persisting antigen. J. Exp. Med. 176, 1273–1281 (1992).
Doherty, P.C., Hou, S. & Tripp, R.A. CD8+ T-cell memory to viruses. Curr. Opin. Immunol. 6, 545–552 (1995).
Matzinger, P. Memories are made of this? Nature 369, 605–606 (1994).
Lucas, K., Small, T., O'Reilly, R.J. & Dupont, B. The development of Epstein Barr virus-specific cellular immunity following allogeneic bone marrow transplantation. Blood 84 (suppl.), 98a (1994).
Lau, L.L., Jamieson, B.D., Somasundaram, S. & Ahmed, R., Cytotoxic T-cell memory without antigen. Nature 369, 648–652 (1994).
Crystal, R.G. Transfer of genes to humans: Early lessons and obstacles to success. Science 270, 404–410 (1995).
Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470–475 (1995).
Blaese, R.M. et al. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475–480 (1995).
Nanda, N.K. & Sercarz, E.E. Induction of anti-self-immunity to cure cancer. Cell 82, 13–17 (1995).
Den Haan, J.M.M. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268, 1476–1480 (1995).
Heslop, H.E. et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum. Gene Ther. 5, 381–397 (1994).
Rill, D.R. et al. An approach for the analysis of relapse and marrow reconstitu-tion after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 79, 2694–2700 (1992).
Boyle, M.J. et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 78, 3004–3011 (1991).
Zimber, U. et al. Geographical prevalence of two types of Epstein-Barr virus. Virology 154, 56–66 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heslop, H., Ng, C., Li, C. et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes. Nat Med 2, 551–555 (1996). https://doi.org/10.1038/nm0596-551
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0596-551
This article is cited by
-
Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
Current Stem Cell Reports (2020)
-
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Nature Medicine (2019)
-
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
Current Hematologic Malignancy Reports (2019)
-
Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial
Bone Marrow Transplantation (2018)
-
Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo
Nature Communications (2018)